Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Completed Clinical Trial
2021: PDY16744 study (Phase II)
For more information contact Victorine Sikati Foko Recruitment will start in few next weeks
Completed Clinical Trials
2023 BIAL (Phase II)
2021: BN42358 study (Phase IIb)
2014: iSTEP study (Phase III)
2011: CONFIDENT-PD study (Phase II)
2010: AFQ056A2217 study (Phase II)
2010: AFQ056A2208 study (Phase II)
Symptoms & Cause
Symptoms generally develop slowly over years. The progression of symptoms is often a bit different from one person to another due to the diversity of the disease. People with PD may experience:
Tremor, mainly at rest and described as pill-rolling tremor in hands. Other forms of tremor are possible
Bradykinesia
Limb rigidity
Gait and balance problems
The cause remains largely unknown. Although there is no cure, treatment options vary and include medications and surgery. While Parkinson’s itself is not fatal, disease complications can be serious.
Diagnose & Treatment
There is no “one way” to diagnose Parkinson’s disease (PD). However, there are various symptoms and diagnostic tests used in combination. Making an accurate diagnosis of Parkinson’s — particularly in its early stages — is difficult.
There is no standard treatment for Parkinson’s disease (PD). Treatment for each person with Parkinson’s is based on his or her symptoms. Treatments can include medications, physical therapy, surgical options, medical marijuana, clinical trials, lifestyle modifications, like getting more rest and exercise.
There are many medications available to treat Parkinson’s symptoms, although none yet that reverse the effects of the disease. It is common for people with PD to take a variety of these medications — all at different doses and at different times of day — to manage symptoms.
Importance of clinical research
Scientists and doctors are working together to find a treatment or prevention technique.
The clinical research will help to attract the attention of the federal and state government as well as the pharmaceutical industry to the growing need and urgency in addressing PD. This is an important first step to better understanding who develops PD and why.
We participate in a number of clinical trials aiming to create advancements for the treatment of Multiple Sclerosis, Stroke, Parkinson’s, Alzheimer’s and Glioblastoma Multiforme (GBM). Our participation allows us to offer many treatments long before they become available to a majority of specialists, giving patients an opportunity to choose from a wide range of care that, while experimental in nature, may possibly be more effective.
Cutting edge treatments aren’t the only reason we conduct clinical trials, nor are they the only reason patients decide to participate. Our involvement gives us the opportunity to develop better protocols and, most importantly, to help advance the treatments themselves.
When it comes to Neurological diseases, large strides have been made in recent years; results that would have been impossible without the participation of Doctors, Nurses and, most of all, patients.
Les immunoglobulines intraveineuses (IgIV) demeurent le traitement de référence pour la PIDC. L’essai ADHERE a récemment confirmé l’efficacité et l’innocuité de l’efgartigimod dans la PIDC. De nombreuses autres thérapies sont actuellement à l’étude.
La CNO participe à des essais cliniques évaluant de nouvelles options thérapeutiques, potentiellement plus efficaces, pour les personnes vivant avec une PIDC.
Études en recrutement
Veuillez vous informer. Au moment de la rédaction, la CNO n’a pas d’essai en recrutement.
Études en cours
LTS 17261 ( SAR 445088/riliprubart) Victorine Sikati Foko Recrutement terminé